Engineered CRISPR/Cas12a Enables Rapid SARS-CoV-2 Detection

CRISPR-ENHANCE demonstrates robust detection across SARS-CoV-2 genes

Our previous study observed that a 3’-end chimeric DNA-extended crRNA enhanced the rate of trans-cleavage activity (Kcat/Km) of LbCas12a by 3.2-fold thus facilitated higher sensitivity in nucleic acid detection (fig. 1A), also known as ENHANCE (Enhanced Analysis of Nucleic acids with CrRNA Extensions). This universal 7-mer DNA extension is spacer-independent and has been tested in various nucleic acid targets such as GFP, HCV, HIV, and SARS-CoV-2 (22). To detect SARS-CoV-2 at low copy number, both wild-type and ENHANCE require a pre-amplification step such as Reverse Transcription Loop-mediated Isothermal Amplification (RT-LAMP), which reverse transcribes SARS-CoV-2 genomic RNA to complementary cDNA and convert it into dsDNA targets (14, 18).

• Download figure
• Open in new tab

Fig. 1. crRNA screening and optimization of ENHANCE for detection of SARS-CoV-2.

(A) Schematic of detection platform using CRISPR-Cas12a highlighting the differences between wild-type and ENHANCE systems. (B) Schematic of SARS-CoV-2 RNA genome and target regions of crRNA used for ENHANCE within the SARS-CoV-2 genomic RNA. (C), (D), and (E) Average fluorescence intensity in RFU of wild-type crRNA (crRNA-WT) and modified crRNA (crRNA-Mod) observed by fluorescence-based reporter assay for N gene, E gene, and RdRp gene, respectively (n = 6). (F) SARS-CoV-2 Genomic RNAs obtained from different geographic regions were tested with CRISPR-Cas12a systems. (G) Comparison of fluorescence intensities when the mutated LbCas12a^D156R is introduced (n = 6). All targeted sequences are genomic RNA obtained from BEI Resources. All fluorescence intensities shown were taken at t = 20 minutes.

In this study, selected regions of the SARS-CoV-2 N gene, E gene, and RdRp gene were targeted with pairs of crRNAs (crN, crE, and crR referred to as crRNA targeting N gene, E gene, and R gene, respectively). These designed crRNAs bear a spacer region of greater than 50% GC content (fig. 1B and table S2). In addition to previously designed crN2, crE1, and crE2 by Broughton et al. (14), we employed three additional crRNAs (crN1, crR1, and crR2) to not only determine optimal crRNAs but also examine the modified LbCas12a trans-cleavage activity compared to the wild-type system. Consistent with our previous study, when targeting SARS-CoV-2 genomic RNA, the modified crRNAs (referred to as crRNA-Mod) exhibited enhanced trans-cleavage activity, up to 5-fold, across all targets compared to the wild-type crRNA (crRNA-WT), indicating significantly higher fluorescence signals via the fluorophore-quencher-based reporter assay results (figs. 1C-E). Improved activity and specificity remained consistent while detecting multiple geographically distributed isolates (Hong Kong, USA, and Italy) (fig. 1F). The ENHANCE system works robustly with a wide range magnesium concentration (3 mM-13 mM), and especially at low magnesium concentration. Thus, ENHANCE enables a potential strategy for screening a library of guide RNAs under various reaction conditions (27).

Previous study has shown that the variant LbCas12a^D156R exhibited a substantially higher gene editing efficiency compared to the wild-type LbCas12a (23-26). We hypothesized that this mutated LbCas12a^D156R would likely increase the trans-cleavage activity due to its correlation between cis-cleavage and trans-cleavage capabilities. Having previously modified crRNA for enhanced LbCas12a trans-cleavage activity, we sought to investigate if we could utilize LbCas12a^D156R to further increase the sensitivity for nucleic acid detection purposes. As a result, the combination of LbCas12a^D156R and 7-mer DNA-extended crRNA showed a significantly higher fluorescence sensitivity than the wild-type LbCas12a and crRNA and a slight enhancement compared to the combination of wild-type LbCas12a and modified crRNA (fig. 1G). This observation later became the basis for the development of ENHANCEv2.

CRISPR-ENHANCE SARS-CoV-2 targeted guide RNA optimization

To seek optimal crRNAs for the ENHANCE platform, we next evaluated the limit of detection (LoD) for the 6 selected modified crRNAs. Quantitative qPCR SARS-CoV-2 genomic RNA were utilized to make a serial dilution theoretically ranging from 200 copies/μL to 0.2 copies/μL followed by an isothermal pre-amplification RT-LAMP step (1000 copies/rxn to 1 copy/rxn). An estimated LoD was determined based on a criterion that the lowest copies/μL having 2/3 of replicates showing at least 5 folds in fluorescence signal compared to that of the no-template control (NTC) within 20 minutes. Out of the six modified crRNAs, crN2 and crE2 designed by Broughton et. al. exhibited the lowest LoD with 0.2 copies/μL and 7.9 copies/μL, respectively (figs. 2A-D). Hence, we selected crN2-Mod and crE2-Mod as the optimal guide RNAs for our clinical validation. The LoDs of crN2-Mod and cRE2-Mod were confirmed by testing 20 replicates of their 1x concentration (0.2 copies/μL and 7.9 copies/μL for crN2 and crE2, respectively) and 1x concentration (0.4 copies/μL and 15.8 copies/μL for crN2 and crE2, respectively). The LoD was established by observing 95% (19/20 replicates) of the target samples being positive. The replicates of both crN2-Mod and crE2-Mod at 1x concentration yielded sufficient positive results, reconfirming the LoD to be 0.2 copies/μL and 7.9 copies/μL, respectively, within 20 minutes of CRISPR reaction (fig. 2E and F). These results demonstrate that the CRISPR-ENHANCE achieved a comparable sensitivity to traditional RT-qPCR testing of SARS-CoV-2 in less than an hour without sophisticated equipment.

• Download figure
• Open in new tab

Fig. 2. Limit of Detection and Exclusivity Testing of ENHANCE.

(A), (B), (C), and (D) Fluorescence intensities in RFU of wild-type crRNA (crRNA-WT) and modified crRNA (crRNA-Mod) in serially diluted samples containing quantitative genomic RNA of SARS-CoV-2 (n = 3). (E) 2/3 of samples detected in (A), (B), (C), and (D) were subject to be tested with 20 different serial dilutions of 1x and 2x number of copies/μL. (F) Scanned images of samples in (E). (G) Exclusivity testing of ENHANCE against highly similar and commonly circulating pathogens. Fluorescence signals were taken at t = 20 minutes. All samples with Ct value ranges were obtained from Zeptometrix.

As a part of exclusivity, we tested a variety of highly similar pathogens to SARS-CoV-2 (SARS-CoV, MERS-CoV, Coronavirus 229E, OC43, SARS, and NL63) and respiratory pathogens commonly detected in nasal swabs or saliva. Notably, the CRISPR-ENHANCE exhibited high specificity towards SARS-CoV-2 with the modified crRNAs targeting N gene and E gene (fig. 2G). No cross reactivity was observed in any of the 31 tested pathogens.

Validation of ENHANCEv1 in patient samples

Having tested detection using the SARS-CoV-2 heat-inactivated virus and genomic RNA for crRNA optimization and LoD determination, we sought to validate the ENHANCEv1 in patient samples to determine whether it still maintains robust detection with clinical conditions. We tested a total of 62 nasal swab samples in which 31 samples were predetermined SARS-CoV-2 positives and the other 31 samples negative. Samples were randomly selected out of the pool and blinded prior to viral RNA extraction. Similar to DETECTR (14), RNAse P gene was used as an internal control for all the nasal swab samples. For the real-time fluorescence-based reporter detection, the criterion for a positive sample is a change in fluorescence signal of 5-fold or greater compared to non-template control (NTC) samples within 20 minutes. Consistent with previous observation, the EHANCEv1 demonstrated a higher sensitivity across all positive samples at low magnesium concentration in a shorter amount of time (fig. 3A). Furthermore, the ENHANCEv1 achieved a 96.7% overall accuracy with a false positive rate and a false negative rate of 3.3% and 3.3%, respectively (fig. S1 and table S3). For lateral flow-based detection, the ENHANCEv1 showed 100% in agreement with the real-time fluorescence-based reporter assay. Similarly, the false positive and false negative rates for this assay were both 3.3% (figs. 3B and S2, S3).

• Download figure
• Open in new tab

Fig. 3. Clinical validation of ENHANCE.

(A) Fluorescence intensity of wild-type crRNA (crRNA-WT) and modified crRNA (crRNA-Mod) detecting SARS-CoV-2 RNA in 62 patient samples using the fluorescence-based reporter assay. Fluorescence signals were taken at t = 20 minutes. (B) Lateral flow assay detecting SARS-CoV-2 RNA in the same 62 patient samples. Heat map shows ratio of band intensity of positive line (top band) to control line (bottom band). Band intensities were analyzed by ImageJ. (C) Representation of lateral flow assay testing 62 patient samples. For full detail, please see supplementary materials. (D) Maximum fluorescence intensity of 62 patient samples against Ct values validated with RT-qPCR.

Lyophilized ENHANCEv2 significantly reduces CRISPR reaction time

We further developed a CRISPR-ENHANCEv2 by combining ENHANCEv1 with the mutated LbCas12a^D156R and a dual reporter comprising a fluorophore FAM, biotin, and a quencher. This reporter can be used as a fluorescence-based reporter as well as a lateral flow-based reporter, both in a single detection assay (fig. 4A). A typical CRISPR reaction requires complexation of crRNA and LbCas12a prior to addition of pre-amplified activator. Therefore, we initially sought to understand whether the complexation of crRNA and LbCas12a can be achieved and remain stable for a period of time prior to testing. If successful, large batches of pre-complexed crRNA:LbCas12a can be manufactured to reduce reaction time and minimize the need for specialized training. We explored if lyophilization can accomplish this objective. Optimal concentrations of crRNA and LbCas12a^D156R were pre-complexed in a mixture containing dual reporter and cleavage buffer. This combined mixture was prepared in different pilot scales: 1 reaction, 5 reactions, and 20 reactions (fig. 4B). By conducting a time study, we observed that these lyophilized pre-complexes maintain high trans-cleavage activity as the liquid version and remain stable for up to 30 days upon storage at room temperature (figs. 4C and S5A). These results help enable scale-up manufacturing, ease of transportation, storage, and reduction in preparation time.

• Download figure
• Open in new tab

Fig. 4. Clinical validation of ENHANCEv2.

(A) Schematic diagram of composition of ENHANCEv2 system. (B) Lyophilized samples in different pilot scales (20, 5, and 1 reactions) of CRISPR reaction used in ENHANCEv2. The CRISPR reaction contains pre-complexed crRNA:LbCas12a^D156R, dual reporter and NEBuffer 2.1. Only RNase-free water and RT-LAMP products are added to activate the reaction. (C) Stability testing of lyophilized CRISPR reaction using ENHANCEv2 with respect to time. (D) Time-course observation of lyophilized CRISPR reaction. Positive samples can be seen by naked eyes under blue light within as low as 2 minutes. (E) Fluorescence intensity of ENHANCEv2 detecting 62 patient samples at t = 2.5 minutes.

Surprisingly, we also observed a significant decrease in reaction time. Using lyophilized CRISPR reaction stored at −20°C after 2.5 months for the fluorescence reporter assay, the fluorescence signal can be seen by naked eyes under blue light after 2 minutes (fig. 4D). When applying the lyophilized ENHANCEv2 towards 62 patient samples, we were able to accurately detect the same 62 patient nasal swab samples with >5-fold change in fluorescence compared to NTC samples in as low as 2.5 minutes (fig. 3F and S4), bringing a total reaction time to 33 minutes (30 minutes of RT-LAMP). This phenomenon strongly suggests that pre-complexed LbCas12a-crRNA promotes faster and easier assay setup.

Protein Expression and Purification

LbCas12a gene fragment was obtained by PCR from the plasmid LbCpf1-2NLS as a gift from Jennifer Doudna (Addgene plasmid # 102566) (31) and subcloned into a linearized CL7-tagged vector (Plasmid #21, TriAltus Bioscience) digested with HindIII and XhoI. The fragments assembly was performed using NEBHiFi Builder (New England Biolabs) following the manufacturer’s protocol. The assembled plasmid was transformed into DH5α (New England Biolabs) competent cells. Individual colonies were picked the next day and inoculated in 10 ml of LB broth, Miller (Fisher Scientific) at 37°C overnight. Cells were harvested, and plasmids were extracted and purified using the Monarch Mini Plasmid prep (New England Biolabs).

For protein expression, 100 ng of the purified plasmid was transformed into BL21(DE3) competent cells (New England Biolabs). Individual colonies were picked and inoculated in 10 ml of Terrific Broth (TB) at 37^°C for 8-10 hours. The culture was then added to 1L TB broth containing 50 μg/ml Kanamycin (Fisher Scientific) and 50 μL antifoam 204 (Sigma Aldrich) and let grown until OD600 = 0.6. The culture was then taken out of the 37^°C incubator and let cooled on ice for 30-45 minutes. Isopropyl β-D-1-thiogalactopyranoside (IPTG, Fisher Scientific) was added to the culture and let grown at 18^°C overnight.

The overnight culture was centrifuged to collect cell pellets the next day. They were resuspended in Lysis Buffer A (2M NaCl, 50 mM Tris-HCl, pH = 7.5, 0.5 mM TCEP, 5% Glycerol, 1mM PMSF, 0.25 mg/ml lysozyme). The mixture was disrupted by sonication, centrifuged at 40000 x g, and filtered through a 0.45 μm filter. The lysate was run through a 1 ml CL7/Im7 column (TriAltus Bioscience) connected to the FPLC Biologic Duoflow system (Bio-Rad). The column was washed for at least 3 cycles of alternating Wash Buffer B (2M NaCl, 50 mM Tris-HCl, pH = 7.5, 0.5 mM TCEP, 5% Glycerol) and Wash Buffer C (50 mM Tris-HCl, pH = 7.5, 0.5 mM TCEP, 5% Glycerol). The column was then eluted by adding 5 mL of SUMO protease (purified from plasmid pCDB302 as a gift from Christopher Bahl, Addgene plasmid# 113673) (32) and flown through in a closed-loop cycle at 30^°C for 1.5 hours. (Optional) To remove SUMO protease, the eluted solution was then concentrated using a 30 kDa MWCO Sartorius Vivaspin Concentrator to 500 μL and subject to size exclusion chromatography in SEC buffer (500 mM NaCl, 50 mM Tris-HCl, pH = 7.5, 0.5 mM TCEP) via the Superdex 200 increase 10/300 GL column (Cytiva). Eluted fractions were collected, pooled together, concentrated, quantified using the NanoDrop (Thermo Fisher), snap frozen in dry ice, and stored at −80^°C until use.

For LbCas12a^D156R expression and purification, the CL7-tagged plasmid obtained by subcloning above was mutated using the Q5® Site-Directed Mutagenesis Kit (New England Biolabs) following the manufacturer’s protocol. The protein expression and purification were the same as described above.

Lyophilization of ENHANCEv2 CRISPR reaction

To make one CRISPR reaction, reagents were mixed in the following order:

This recipe was scaled up accordingly to make 5x and 20x reaction aliquots. These aliquots were then subject to lyophilization using the Labconco freeze dryer for 2-4 days.

CDC RT-qPCR assay

Patient samples were obtained from University of Florida (UF) Clinical and Translational Science Institute and Boca Biolistics by following the guidelines listed in the approved UF Institutional Review Board protocol (IRB202000781). The samples were re-validated with real time RT-qPCR. The reactions were performed using the CDC recommended Quantabio qScript XLT One-Step RT-qPCR ToughMix (Catalog# 95132-100) and TaqMan probes and primer sets (add citation) and measured using the ViiA 7 Real-Time PCR System. RT-qPCR quantification was performed using amplification plots generated by the ViiA 7 software.

Viral nucleic acid extraction

For crRNA screening and optimization, LoD estimation, inclusivity testing and specificity testing, viral RNA extraction was performed using the Lucigen QuickExtract™ DNA Extraction Solution (Cat # QE09050). Viral samples were diluted with QuickExtract™ in a 1:1 (v/v) ratio and incubated at 65°C for 15 min and 98°C for 2 min.

For clinical validation experiments, all patient samples were extracted using Maxwell® RSC 16 automated nucleic acid extraction instrument. Maxwell® RSC Viral Total Nucleic Acid Purification Kit (Cat# AS1330, as recommended by CDC) was used for all extractions following manufacturer’s protocol.

RT-LAMP reactions

A set of 6 LAMP primers were designed for each gene using the freely available PrimerExplorer software (https://primerexplorer.jp/e/) (33). The designed primers were synthesized by Integrated DNA Technologies. A 10x primer mix for each gene was created by mixing the 6 primers to a final concentration of 1.6 μM (FIP/BIP), 0.8 μM (LB/LF) and 0.2 μM (F3/B3). RT-LAMP reactions were performed using the WarmStart® Colorimetric LAMP 2X Master Mix (New England Biolabs). RT-LAMP master mix for N reactions (including the positive and negative control) were prepared as follows:

The prepared master mix was incubated at 65°C for 30 min to allow for adequate amplification. The amplified products were tested downstream using the CRISPR ENHANCE assays.

crRNA screening and optimization of ENHANCE for detection of SARS-CoV-2

Genomic RNA from SARS-CoV-2, Isolate USA-WA1/2020 (NR-52285) obtained from Biodefense and Emerging Infections Research Resources Repository (BEI resources), was spiked in nucleic acid extract obtained from a healthy donor. The spiked extract was amplified for the target genes (N1, N2, E1, E2, R1 and R2) using RT-LAMP. The amplified products were then detected using wild type CRISPR/Cas12a as well as CRISPR ENHANCEv1.

Inclusivity Testing

SARS-CoV-2 Genomic RNA of isolates obtained from different geographic regions such as Italy, Hong Kong and USA (NR-52498, NR-52388 and NR-52285) obtained from BEI resources were spiked in nucleic acid extract obtained from the nasopharyngeal swab of a healthy donor. Target genes were amplified using RT-LAMP protocol described earlier and detected using CRISPR ENHANCEv1.

Specificity testing

To demonstrate specificity of our assay towards SARS-CoV-2 we obtained 31 highly similar and commonly circulating pathogens from ZeptoMetrix (Cat# NATPPQ-BIO, Cat# NATRVP-3, Cat# NATPPA-BIO). Each pathogen was spiked in a matrix composed of nasopharyngeal swab from a healthy donor. The spiked nasal swab was extracted using Lucigen QuickExtract™ and target genes within the extracted nucleic acids were amplified using RT-LAMP. The amplified products were detected using CRISPR ENHANCEv1.

Estimation of LoD

Nasopharyngeal swab sample from a healthy donor was mixed with an equal volume of Lucigen QuickExtract™ DNA Extraction Solution (Cat # QE09050) and incubated at 65°C for 15 min and 98°C for 2 min to extract nucleic acids from the swab. Mock clinical patient samples were prepared by serially diluting the nucleic acid extract with Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-Related Coronavirus 2 (BEI NR-52347) to a final concentration range of 200 copies/μL to 0.2 copies/μL. The LoD for each gene was determined by amplifying the gene using RT-LAMP and then detecting it at the indicated concentrations with CRISPR ENHANCEv1. The LoDs for N2 gene and E2 gene were confirmed by testing with 20 replicates at 1x and 2x of the previously estimated LoD for each gene.

Fluorescence-based reporter detection assay

All fluorescence-based detection experiments were performed in a 384-well plate. The following recipe was used for CRISPR/Cas complexation:

The prepared master-mix was incubated at 37°C for 15 min after which it is added to a 384-well plate containing 0.2 μL of 100 μM Fluorophore-Quencher (FQ), 25.8 μL of nuclease-free water and 2 μL of RT-LAMP product. Emitted fluorescence resulting from Cas12a based trans-cleavage was measured using BioTek Synergy 2 microplate reader with fluorescence measurement at excitation and emission wavelengths of 485/20 and 528/20, respectively, every 2.5 minutes. For a 96-well plate format all reagents are scaled up 2.5 times.

Lateral Flow detection assay

The following recipe is used for the lateral flow assay:

2 μL of the corresponding RT-LAMP product was added to the above mixture and incubated at 37°C for 20 minutes. A paper strip is then dipped in the reaction tube and the presence or absence of the target gene is determined based on a visual readout after 2 mins. Lateral flow band signals were later quantified by ImageJ.

Clinical validation of patient samples using CRISPR ENHANCE

62 patient samples underwent a blind test. Random samples were selected from the pool, and nucleic acids extracted from those patient samples were subjected to RT-LAMP based amplification of N2 gene, E2 gene and RNASE-P gene. The same amplified RT-LAMP products were then detected using both the fluorescence-based reporter detection assay and the lateral flow assay with ENHANCEv1 and with the lyophilized ENHANCEv2.